# A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

> **NCT02921828** · — · COMPLETED · sponsor: **Celgene** · enrollment: 1149 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02921828
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-30
- **Primary completion:** 2015-12-10
- **Final completion:** 2015-12-10
- **Target enrollment:** 1149 (ACTUAL)
- **Last updated:** 2022-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921828, "A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02921828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*